218 related articles for article (PubMed ID: 15746052)
1. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
2. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
3. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study.
Markopoulos C; Polychronis A; Zobolas V; Xepapadakis G; Papadiamantis J; Koukouras D; Lappas H; Gogas H
Breast Cancer Res Treat; 2005 Sep; 93(1):61-6. PubMed ID: 16184460
[TBL] [Abstract][Full Text] [Related]
4. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
Mieog JS; Morden JP; Bliss JM; Coombes RC; van de Velde CJ;
Lancet Oncol; 2012 Apr; 13(4):420-32. PubMed ID: 22265698
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
Fallowfield LJ; Bliss JM; Porter LS; Price MH; Snowdon CF; Jones SE; Coombes RC; Hall E
J Clin Oncol; 2006 Feb; 24(6):910-7. PubMed ID: 16484701
[TBL] [Abstract][Full Text] [Related]
6. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
[TBL] [Abstract][Full Text] [Related]
7. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
8. Exemestane for primary prevention of breast cancer in postmenopausal women.
Zhang Y; Simondsen K; Kolesar JM
Am J Health Syst Pharm; 2012 Aug; 69(16):1384-8. PubMed ID: 22855103
[TBL] [Abstract][Full Text] [Related]
9. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
Schilder CM; Seynaeve C; Beex LV; Boogerd W; Linn SC; Gundy CM; Huizenga HM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
J Clin Oncol; 2010 Mar; 28(8):1294-300. PubMed ID: 20142601
[TBL] [Abstract][Full Text] [Related]
10. Reversal of skeletal effects of endocrine treatments in the Intergroup Exemestane Study.
Coleman RE; Banks LM; Girgis SI; Vrdoljak E; Fox J; Cawthorn SJ; Patel A; Bliss JM; Coombes RC; Kilburn LS
Breast Cancer Res Treat; 2010 Nov; 124(1):153-61. PubMed ID: 20730486
[TBL] [Abstract][Full Text] [Related]
11. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.
Francini G; Petrioli R; Montagnani A; Cadirni A; Campagna S; Francini E; Gonnelli S
Br J Cancer; 2006 Jul; 95(2):153-8. PubMed ID: 16835585
[TBL] [Abstract][Full Text] [Related]
12. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Handratta V; Long BJ; Goloubeva OG; Ingle JN; Brodie AM
Clin Cancer Res; 2004 Nov; 10(21):7375-81. PubMed ID: 15534114
[TBL] [Abstract][Full Text] [Related]
13. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
Garrone O; Bertelli G; Principe E; Lewis PD; Occelli M; Miraglio E; Merlano MC
Tumori; 2014; 100(6):620-4. PubMed ID: 25688495
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
Gonnelli S; Cadirni A; Caffarelli C; Petrioli R; Montagnani A; Franci MB; Lucani B; Francini G; Nuti R
Bone; 2007 Jan; 40(1):205-10. PubMed ID: 16904960
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
[TBL] [Abstract][Full Text] [Related]
19. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
20. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
